The mTORC1 inhibitor rapamycin and derivative compounds (rapalogues) are used for treatment of various types of cancer, in addition to Tuberous Sclerosis Complex (TSC), an autosomal dominant disorder caused by pathogenic variants in either TSC1 or TSC2 [53]. This evidence concerns the gene TSC1 and cancer.